Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new genetic medicines for systemic and renal diseases. With our STRIKE (Selectively Targeting RNA Into KidnEy) platform, we are using a proprietary approach to create ligand-RNA conjugate drugs designed for receptor-mediated update by specific kidney cell types, resulting in gene silencing of disease-modifying target genes. Judo Bio’s initial pipeline programs are megalin-STRIKERs that use the megalin receptor family to selectively deliver siRNA therapeutics to the proximal tubule of the kidney to silence mRNA expression of specific solute carrier proteins (SLCs), thereby inhibiting the uptake of circulating solutes linked to systemic diseases.
Company Details
- Employees
- 21
- Address
- Cambridge, Ma 02139, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://judo.bio/
- HQ
- Cambridge, MA
Judo Bio Questions
Judo Bio's website is https://judo.bio/
Judo Bio's LinkedIn profile is https://www.linkedin.com/company/judobio
Judo Bio has
21 employees.
View email and phone details for 21
employees at Judo Bio.
Judo Bio's industry is
Biotechnology Research
Judo Bio's top competitors are
Upstream Bio,
Atlas Venture,
City Therapeutics,
Scholar Rock,
Immatics,
Gritstone Bio,
Triveni Bio,
Turnstone Biologics,
Kailera Therapeutics,
Purespring Therapeutics.
Judo Bio's categories are Biotechnology Research
